Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-2009 · 1 trial · 5 indications
ORR is the proportion of patients in the efficacy-evaluable population with a best response of Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Central Radiology Review (CRR)
| Arm | Type | Description |
|---|---|---|
| ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative | EXPERIMENTAL | CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer |
| ARM B - CX-2009 Monotherapy, TNBC | EXPERIMENTAL | CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC) |
| ARM C - CX-2009 Combination therapy, TNBC | EXPERIMENTAL | CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC |
| Name | Type | Description |
|---|---|---|
| CX-2009 | DRUG | Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W) |
| CX-072 | DRUG | Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W) |
INCLUSION CRITERIA: * Arm A: inoperable, locally advanced or metastatic HR-positive/HER2-negative breast cancer. Patients must have received 0 to 2 prior cytotoxic chemotherapy in the inoperable, locally advanced, or metastatic setting * Arm B and Arm C: inoperable, locally advanced or metastatic T...
CX-2009 is an investigational small molecule being developed for the treatment of neoplasms, specifically advanced breast cancer. It is being studied as a monotherapy and in combination with CX-072 in patients with conditions including triple-negative breast cancer and hormone receptor positive/HER2 negative breast cancer.
CX-2009 is being developed by CytomX Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CTMX. The company is conducting clinical research to evaluate the safety and antitumor activity of this investigational therapy in advanced breast cancer.
CX-2009 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy. The Phase 2 trial evaluating CX-2009 in advanced breast cancer has been completed.
CX-2009 has been studied in one clinical trial, identified as NCT04596150. This Phase 2 study evaluated the safety and antitumor activity of CX-2009 as a monotherapy and in combination with CX-072 in advanced breast cancer. The trial enrolled 125 participants and has been completed.
No, CX-2009 and CX-072 are different investigational drugs. In the clinical trial NCT04596150, CX-2009 was studied both as a monotherapy and in combination with CX-072. The trial was designed to evaluate the safety and antitumor activity of CX-2009 alone and when combined with CX-072 in advanced breast cancer.